Hanjo Hennemann is co-founder and managing director (CEO) of VEROVACCiNES GmbH, a German biopharmaceutical company developing a novel class of yeast-based animal vaccines. From 2014-2017 he was driving the spin-out process of VEROVACCiNES from the University of Halle-Wittenberg, Germany. From 2007 to 2014 he founded and headed the biopharmaceutical company Nexigen GmbH as CEO/CSO. Previously he was principal investigator at the research center caesar, Bonn, Germany where he established the discovery technology for peptide drugs and the foundation of Nexigen. Before that he had postdoctoral appointments at the University of Essen and the University of California, San Diego, USA. He was awarded an Alexander-von-Humboldt Fellowship for the post-doctoral work in the group of Prof Michael Karin (University of California, San Diego) in signal transduction and growth control. Dr Hennemann earned a diploma and doctorate in molecular genetics from the University of Bonn, Germany.